A woman presents at term pregnancy for first antenatal visit and tests positive for HIV in screening and confirmatory tests. Next step in management is?

Okay, let me tackle this question. The patient is a woman in term pregnancy with a positive HIV test. The question is about the next step in management. First, I need to recall the standard protocol for HIV in pregnancy.

HIV management during pregnancy is crucial to prevent mother-to-child transmission. The core concept here is the prevention of vertical transmission. The key steps involve antiretroviral therapy (ART) to suppress the viral load, which is the most effective way to reduce transmission risk.

The correct answer should involve initiating ART. The options might include other steps like CD4 count, viral load testing, or delivery planning, but the immediate next step after confirming HIV is starting ART. Let me check the options again. Wait, the options aren't provided here, so I need to think about common distractors.

Common mistakes might include starting ART only if the viral load is high, but guidelines recommend ART regardless of CD4 or viral load in pregnant women. Other options might suggest waiting until later in pregnancy, but the first step is immediate ART initiation. Also, delivering in a hospital is important, but that's after starting ART.

Clinical pearls: The main goal is to start ART as soon as possible to reduce transmission risk. The WHO and CDC guidelines emphasize early ART initiation. So the next step after diagnosis is to start ART. Also, monitoring viral load and CD4 counts are part of the follow-up but not the immediate next step.

**Core Concept**
HIV-positive pregnant women require immediate initiation of antiretroviral therapy (ART) to prevent vertical transmission. The primary goal is to suppress maternal viral load to undetectable levels, significantly reducing perinatal transmission risk.

**Why the Correct Answer is Right**
The next step is to start the patient on a **combination ART regimen** (e.g., tenofovir + emtricitabine + dolutegravir). ART reduces maternal viremia, prevents placental transmission, and is safe in pregnancy. Early initiation also protects maternal health by preserving CD4+ T-cells and delaying disease progression. Dolutegravir is preferred due to high efficacy and low resistance, though it should be avoided in the first trimester due to neural tube defect concerns (though risk remains low with folate supplementation).

**Why Each Wrong Option is Incorrect**
**Option A:** "Wait until 34 weeks to start ART" is incorrect. Delaying ART increases transmission risk. Immediate initiation is standard.
**Option B:** "Start ART only if CD4 < 350" is outdated. Current guidelines (WHO/US CDC) recommend ART for all HIV-positive pregnant women regardless of CD4 count. **Option D:** "Schedule cesarean delivery without ART" is incorrect. Cesarean delivery reduces transmission risk only if viral load is detectable; ART remains the cornerstone. **Clinical Pearl / High-Yield Fact** Never delay ART in HIV-positive pregnant patients—even with high CD4 counts. The **PEP-07 trial** confirmed that early ART initiation reduces vertical transmission to <1%. Avoid dolutegravir in the first trimester if possible, but prioritize ART compliance over timing concerns. **Correct Answer: C. Initiate antiretroviral therapy (ART) with tenofovir, emtricitabine, and dolutegravir**

✓ Correct Answer: C. Sta A immediately